{"id":"NCT03334396","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-23","primaryCompletion":"2018-12-06","completion":"2019-08-16","firstPosted":"2017-11-07","resultsPosted":"2020-01-18","lastUpdate":"2020-08-18"},"enrollment":660,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"Baricitinib","otherNames":["LY3009104"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"4 milligram (mg) Baricitinib","type":"EXPERIMENTAL"},{"label":"2 mg Baricitinib","type":"EXPERIMENTAL"},{"label":"1 mg Baricitinib","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"4 mg Baricitinib Maximum Extended Enrollment Cohort","type":"EXPERIMENTAL"},{"label":"2 mg Baricitinib Maximum Extended Enrollment Cohort","type":"EXPERIMENTAL"},{"label":"1 mg Baricitinib Maximum Extended Enrollment Cohort","type":"EXPERIMENTAL"},{"label":"Placebo Maximum Extended Enrollment Cohort","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of baricitinib as monotherapy in participants with moderate to severe atopic dermatitis.","primaryOutcome":{"measure":"Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a â‰¥ 2 Point Improvement (Placebo, 2 mg, or 4 mg Baricitinib)","timeFrame":"16 Weeks","effectByArm":[{"arm":"Placebo","deltaMin":4.8,"sd":null},{"arm":"2 mg Baricitinib","deltaMin":11.4,"sd":null},{"arm":"4 mg Baricitinib","deltaMin":16.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.020"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":14},"locations":{"siteCount":93,"countries":["Czechia","Denmark","France","Germany","India","Italy","Japan","Mexico","Russia","Taiwan"]},"refs":{"pmids":["36255569","34688290","34275122","33826132","33222559"],"seeAlso":["https://www.lillytrialguide.com/en-US/studies/eczema/JAHL#?postal="]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":249},"commonTop":["Nasopharyngitis","Headache","Diarrhoea","Urinary tract infection","Pyrexia"]}}